Systemic Sclerosis and Environmental Chemical Exposure
Systemic sclerosis (scleroderma) is a rare autoimmune fibrotic disease characterized by skin and internal organ fibrosis driven by aberrant TGF-beta signaling. Environmental chemical exposures—particularly silica and solvents—are established triggers, and PFAS are emerging as additional candidates.
PFAS and TGF-beta Fibrotic Signaling
PFAS compounds activate TGF-beta signaling pathways that drive fibroblast differentiation into myofibroblasts—the cellular mediators of pathological fibrosis. PFAS-exposed cells show increased collagen deposition and reduced matrix metalloproteinase activity, creating a pro-fibrotic cellular environment consistent with scleroderma pathogenesis.
Epidemiological Signals
Occupational studies of fluorochemical workers show elevated rates of scleroderma and related connective tissue diseases compared to reference populations. Geographic clustering of scleroderma near PFAS industrial sites provides additional epidemiological support for chemical-fibrosis associations.
Clinical Implications
Rheumatologists evaluating early connective tissue disease symptoms—particularly Raynaud’s phenomenon, skin thickening, and esophageal dysmotility—in patients from PFAS-contaminated areas should consider chemical exposure history. Early exposure reduction may limit progressive fibrotic damage.